Background: Eosinophilic esophagitis (EoE) is a chronic antigen-mediated clinicopathologic disease of the esophagus characterized by an eosinophil-predominant inflammatory infiltrate. A clinical hallmark is extensive tissue remodeling including basal zone hyperplasia, fibrosis, and angiogenesis. However, the cellular mechanisms responsible for these processes are not fully defined. We hypothesized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist cytokine linked with eosinophil survival and activation) would be protective in a preclinical model of EoE. Methods: Eosinophilic esophagitis-like esophageal inflammation was induced in the L2-IL5 OXA
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was first defined because of its ability to generate colonies of mature granulocytes and macrophages from myeloid progenitors in vitro and is now known as a key mediator of eosinophilopoiesis. Granulocyte-macrophage colony-stimulating factor is induced by bacterial endotoxins and certain cytokines in many cell types including leukocytes (i.e. macrophage, mast cells, and T cells) and nonleukocytes (i.e. fibroblasts, endothelial, mesothelial, and epithelial cells) with actions on cells expressing the GM-CSF-Ra such as eosinophils, basophils, DC-like cells, monocytes/macrophages, and neutrophils. Besides eosinophil progenitor proliferation and maturation, GM-CSF is now recognized to have a range of functions on mature eosinophils including dose-dependent eosinophil priming, migration, and degranulation (7) (8) (9) . In addition, GM-CSF may also induce angiogenesis in multiple tissues by activating both proliferation and migration of endothelial cells (10) (11) (12) (13) .
We hypothesized that targeting GM-CSF would be protective in a preclinical model of EoE. The purpose of this study was to evaluate the potential use of an anti-GM-CSF antibody treatment on the inflammatory patterns related to esophageal eosinophilia, epithelial basal zone hyperplasia, and angiogenesis as a measure of postinflammatory epithelial remodeling. Using our previously described L2-IL5 OXA mouse model of EoE (14), we show that treatment with an anti-mouse GM-CSF monoclonal antibody significantly reduced epithelial eosinophilia, basal cell hyperplasia, and angiogenesis. The data support the importance of GM-CSF in the accumulation of eosinophils in EoE, suggesting it as a potential target for further clinical investigation.
Materials and methods

Mice
All studies were performed with male or female L2-IL5 mice on a C57BL/6J background generated as previously described (14) . Animals were maintained in micro-isolator cages housed in a specific-pathogen-free facility at the University of Colorado. Age-and sex-matched L2-IL5 mice were used as controls. Studies involving animals were performed in accordance with National Institutes of Health, University of Colorado IACUC guidelines.
Induction of experimental EoE in L2-IL5
OXA mice using 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone or OXA)
Induction of esophageal eosinophilic inflammation in mice (L2-IL5 OXA EoE) was established using a 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone or OXA) (Sigma, St Louis, MO, USA) contact hypersensitivity protocol as previously described (Fig. 3A ) (14) . Briefly, on day 0 of the protocol, anesthetized mice were shaved on the abdomen and oxazolone was applied to the skin surface (150 ll of a 3% (w/v) solution of OXA in 4 : 1 acetone-olive oil vehicle) to initiate the sensitization phase of the protocol (15) . On days 5, 8, and 12, mice were challenged by an intra-esophageal gavage of 100 ll of a 1% (w/v) OXA in 30% ethanol/ olive oil vehicle. Vehicle control L2-IL5 mice were sensitized as above and challenged with vehicle alone. All mice were assessed 24 h following the last OXA challenge (protocol day 13).
In some studies, a GM-CSF depleting antibody was administered to mice. These studies were completed using a monoclonal rat IgG2a antibody specific for murine GM-CSF (Clone # MP122E9) or monoclonal rat IgG2a isotype control antibody (Clone # 54447; R&D Systems, Minneapolis, MN, USA). Experimental animals were injected with four intraperitoneal (i.p.) doses of anti-GM-CSF antibody (0.5 mg/mouse) or IgG2a isotype control on days 5, 8, 10, and 12 during experimental esophagitis (Fig. 3A) . Mice were killed 24 h following final treatment (day 13).
Tissue processing and immunohistochemical assessment of tissues
Whole-length esophageal tissues were removed and fixed with 10% neutral-buffered formalin, processed, paraffinembedded, and cut into 5-lm sections. Sections were stained with hematoxylin and eosin (H&E) (Sigma) or subjected to immunohistochemistry for eosinophil major basic protein-1 (MBP-1; Clone MT-14.7) (Lee Labs, Mayo Clinic, AZ, USA), Ki67 (Dako, Carpinteria, CA, USA) to assess cell proliferation, both as previously described (14) or CD31 (PECAM) (Abcam, Cambridge, MA, USA). MBP-1 immuno-positive cells were visualized with permanent red chemotrope, Ki67 immuno-positive cells were visualized with DAB chemotrope (Dako), and the slides were counterstained with Methyl Green (Vector Laboratories, Burlingame, CA, USA). CD31 (PECAM) immunopositive cells were visualized with a fluorescently tagged Alexa Fluor 488 antibody (Invitrogen, Grand Island, NY, USA), and slides were counterstained with DAPi (Invitrogen). Control sections replaced the primary antibody in each case with a rat IgG isotype control antibody (Vector Laboratories). Quantification of either MBP-1 or Ki67 immuno-positive cells was determined by gathering the numerical averages of nine nonoverlapping high-power fields (0.26 mm 2 ) per esophagus (three distal, three mid, and three proximal). Mean vessel density was determined as previously described (16) from an average of nine nonoverlapping high-power fields per esophagus (three distal, three mid, and three proximal). Numbers are presented as a mean AE SEM.
Esophageal leukocyte isolation, quantification, and flow cytometric analysis Esophageal leukocytes were isolated as previously described (14) . Briefly, esophagi were resected, cut longitudinally, washed in PBS, and then digested with collagenase (Sigma) as previously described for other intestinal tissues (17) . Cell counts and viability of recovered leukocytes were determined with a hemocytometer and trypan blue exclusion. 
Cell culture
EPC2-hTERT immortalized human esophageal epithelial cells were cultured as previously described (18) . EPC2-hTERT cells were seeded at 60 000 cells per well of a 24-well plate and 24 h after plating cells were switched to high-calcium (1.8 mM) medium for a further 48 h. Cells were then washed and treated for 24 h with varying concentrations of rhGM-CSF (R&D Systems). Cells were harvested for mRNA analysis using RLT buffer from Qiagen RNeasy kits (Qiagen, Valencia, CA, USA).
RNA isolation and real-time RT-PCR
Total RNA was prepared from whole distal esophageal tissues with RNeasy Mini Kits (Qiagen) and handheld laboratory homogenizer (PRO Scientific, Oxford, CT, USA). Firststrand cDNA synthesis was performed from 500 ng of total RNA using the High Capacity cDNA archive kit (Applied BioSystems, Foster City, CA, USA). Transcript expression was assessed using Taqman Gene Expression Assays Taqman probes (Applied Biosystems). rtRT-PCR was performed with ABsolute TM Blue QPCR ROX Mix (Thermo Scientific, Surrey, UK). Thermocycling and analysis were performed with ABI-7300 System and software (Applied BioSystems, Foster City, CA, USA). Data were normalized to 18S expression and calculated as RQ (Relative Quantity; 2
ÀDDCt , where C t is cycle threshold) for each sample.
GM-CSF protein assessment of esophageal tissue
Esophagi were resected, cut longitudinally to expose the luminal surface, washed in PBS, snap-frozen, and stored at À80°C prior to use. Tissues were homogenized in MSD lysis buffer containing Roche complete mini protease inhibitor cocktail (Sigma) and assessed for GM-CSF protein content using a mouse GM-CSF-specific Mesoscale Assay (as per the manufacturer's instructions) [Meso Scale Diagnostics (MSD), Rockville, MD, USA] or total protein content using BCA Assay (Thermo Fisher, Waltham, MA, USA).
Statistical analysis
Statistical analyses of data outcomes were performed by Student's t-test. Data are expressed as means AE SEM. A P-value of ≤0.05 was considered as statistical significance although in some cases, higher levels of significance are noted and described in the figure legends where applicable. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Results
GM-CSF expression is increased in esophageal eosinophilia
To understand the potential impact of GM-CSF on esophageal eosinophilia, we performed three sets of experiments (1). We first tested to see whether GM-CSF expression was elevated in the esophagus linked with the eosinophil-predominant inflammation occurring in the L2-IL5
OXA mouse model of EoE. After 8 days, we examined both mRNA and protein expression in the esophageal tissue and found both to be significantly increased (mRNA: 1.3 AE 0.3 vs 9.0 AE 1.9, P ≤ 0.05; Protein: 128 AE 35 vs 556 AE 179 pg/ml, P ≤ 0.05, OXA vs Veh-Ctrl) (Fig. 1A ,B) (2). We tested whether GM-CSF would stimulate esophageal epithelial cells to release pro-allergic molecules given that epithelial cells exposed to GM-CSF are associated with perpetuation of atopic inflammatory conditions such as atopic dermatitis (19, 20) . Our results showed that exposure of the human esophageal epithelial cells to rhGM-CSF induced the concentration-dependent production of GM-CSF in vitro (1.97 AE 0.47-fold increase, anti-GM-CSF vs IgG-Ctrl, P ≤ 0.05) (Fig. 1C) ) and presented as absolute cell numbers, with macrophage being the most abundant of these three MHCII bearing populations (Fig. 2Bii) . Assessment of cell frequency in mouse esophagi found that neutrophils were rare compared to other leukocytes such as eosinophils (Fig. 2Bii) . Immunofluorescent assessment of GM-CSF-Ra and SiglecF revealed costaining for both to a significant degree compared to cells of the lamina propria that were positive for GM-CSF-Ra alone (Fig. 2Ci-iii) .
Anti-GM-CSF antibody treatment attenuates esophageal epithelial eosinophilia
We tested the hypothesis that depletion of GM-CSF protein by antibodies would reduce the esophageal eosinophilia in L2-IL5
OXA EoE mice. Experimental groups of animals were given anti-GM-CSF antibody (via intraperitoneal injection, control animals received isotype-matched serum immunoglobulin) beginning day 5, the day of the first intraesophageal challenge and on days 8, 10, and 12 after induction of esophagitis (Fig. 3A) . Anti-GM-CSF treatment lead to a significant decrease in epithelial eosinophilia as measured by counting intact eosinophils and assessing eosinophil MBP-1 staining compared to anti-IgG2a isotype control-treated L2-IL5
OXA EoE mice (Fig. 3B,Ci) . The pattern of inhibition appeared to be most notable in the distal and middle esophagus. In addition, eosinophilia in the lamina propria was also reduced significantly (Fig. 3Cii ) but no effect was observed on eosinophilia in the muscle layers (Fig. 3Ciii) .
To elucidate whether these effects were locally restricted within the esophagus or were as a result of effects on eosinophil development and circulation, peripheral eosinophils were assessed from the spleen and bone marrow compartments by flow cytometry (Live, SSC-hi, CD45 anti-GM-CSF to those that underwent anti-IgG 2A control antibody treatment. Statistical significance was assessed using the Students' t-test, *P < 0.05. Data are expressed as means AE SEM.
Anti-GM-CSF antibody treatment does not affect esophageal eosinophil maturation, activation markers, or eosinophil chemoattractant expression
Given its role as an eosinophilopoietin, we examined whether depletion of GM-CSF during esophagitis would affect the maturation status of eosinophils in mice treated with anti-GM-CSF when compared to those treated with anti-IgG2a control (Fig. 4) (Fig. 4A) . We then examined these cells for the level of expression of various maturation and activation markers. We found no effect of anti-GM-CSF on the expression levels of any of these selected markers (Fig. 4B) . We also examined whether anti-GM-CSF would affect esophageal tissue expression of eosinophil chemokines CCL11 and CCL24 (eotaxins 1 and 2) and found no effect (Fig. 4C) . 
Anti-GM-CSF antibody treatment resolves basal cell hyperplasia and epithelial remodeling
Next, the effects of anti-GM-CSF depletion on epithelial remodeling and basal cell hyperplasia were assessed (Fig. 5) . A substantial improvement in basal cell hyperplasia and the homeostatic localization of proliferative cells as demarcated by Ki67 immunohistochemistry was observed following treatment (Fig. 5A) . When enumerated, the most significant improvement was observed in the proximal and distal esophagus (Fig. 5B) .
Anti-GM-CSF antibody treatment decreases blood vessel density and angiogenic factor production
Finally, the role of GM-CSF in esophageal vascular remodeling in the context of eosinophilic inflammation was examined (Fig. 6) . PECAM (CD31)-positive vessel density was enumerated, and it was found that anti-GM-CSF treatment resulted in a lower vessel density compared to IgG control-treated L2-IL5 OXA animals (Fig. 6A,B) . When the expression of angiogenic stimulating factors including angiogenin and angiopoietins 1 and 2 was assessed, it was also determined that anti-GM-CSF treatment led to significantly reduced levels of these growth factors ( Fig. 6C-E) . In addition, GM-CSF blockade significantly decreased esophageal levels of endothelial markers PECAM and von Wilebrand Factor (vWF) compared to IgG-treated controls (Fig. 6F,G) .
Interestingly, no difference in the expression levels of the activation markers CDH5, VCAM, or VEGF-A was detected ( Fig. 6H-J) . We also assessed each of these molecular markers in the context of uninflamed L2-IL5 VEH esophagi and found a significant decrease in selected markers (VWF: 40% decrease AE4%, P < 0.05, ANG2: 60% decrease AE11%, P < 0.05, PECAM: 62% decrease AE16%, P < 0.05) in the esophagi treated with anti-GM-CSF antibody when compared to L2-IL5 VEH IgG control-treated animals. However, importantly, this did not lead to a decrease in the number of PECAM+ blood vessels in anti-GM-CSF antibody-treated uninflamed L2-IL5 VEH mice (0.08 AE 0.03 vs 0.07 AE 0.02,
Thus, therapeutic intervention with anti-GM-CSF limits epithelial remodeling and angiogenic activation during active disease in the L2-IL5 OXA model of EoE.
Discussion
In our studies, we directly examined the physiologic impact of targeting GM-CSF, a crucial eosinophilopoietin in the pathogenesis of esophageal eosinophilia and epithelial remodeling in the L2-IL5 OXA mouse model of EoE. We demonstrated that GM-CSF expression is increased in the L2-IL5 OXA mice and that a targeted antibody-mediated GM-CSF blockade results in a significant decrease in epithelial eosinophilia, decreased epithelial basal cell hyperplasia, and decreased angiogenesis, resulting in overall attenuation (21) (22) (23) (24) (25) (26) , these studies failed to demonstrate clinical benefit (5, 6) . We sought to understand the potential role of another therapeutic target, GM-CSF, to address the need for alternative treatment options. Previous studies have demonstrated that targeting GM-CSF influences leukemogenesis in an in vitro model of chronic myelomonocytic leukemia (27) , inflammatory responses in experimental arthritis (28, 29) , reduced tissue macrophage in rat model of myocardial infarction (30) , and reduced Amyloid b1-42 and microglial activity in a mouse model of Alzheimer's disease (31) . Two studies have also directly examined the influence of anti-GM-CSF therapy on bronchoalveolar lavage fluid eosinophilia in mouse models of allergic airway inflammation (32, 33) , and an ongoing trial is examining anti-GM-CSF antibodies' role in subjects with asthma. Moreover, two human clinical trials are ongoing, studying the effects of anti-GM-CSF in rheumatoid arthritis (34, 35) . While many preclinical and clinical studies targeting GM-CSF for inflammatory diseases are ongoing, the role of GM-CSF and the impact of anti-GM-CSF therapies in EoE have not been assessed to date.
Here, we provide evidence for the increased presence of GM-CSF and for its role in esophageal epithelial eosinophilia in the L2-IL5
OXA mouse model of EoE. Previous studies using eotaxin À/À genetically targeted mice in a mouse model of EoE still accumulated esophageal eosinophils, implicating additional chemotactic axes in esophageal epithelial recruitment (23) . We show that reduced epithelial eosinophilia is not a result of effects of anti-GM-CSF treatment on esophageal eosinophilic chemokines eotaxin-1 or -2 or on eosinophil development and circulation. Granulocyte-macrophage colony-stimulating factor acts on mature eosinophils to elicit priming, migration, and degranulation (7) (8) (9) . Here, we show no effect of anti-GM-CSF therapy on esophageal eosinophil expression of maturation or activation markers. These findings suggest that decreased esophageal epithelial eosinophilia in the L2-IL5 OXA EoE mouse model may be acting through local effects of GM-CSF within the esophagus, possibly limiting intra-epithelial eosinophil survival or indirectly via antigen-presenting cells. Our data would also suggest that GM-CSF has a direct role of vascular activation and remodeling, which may also limit eosinophil trafficking to the inflamed esophagus. Previous literature supports the effects of GM-CSF on cells of the mature myeloid lineage including PMNs (polymorphonuclear leukocytes), monocytes/macrophage, basophils, and eosinophils (36 (5, 6) . Granulocyte-macrophage colony-stimulating factor along with IL-5 and IL-3 are a triad of important, although thought to be potentially redundant, cytokines associated with eosinophil development in the bone marrow. This study demonstrates for the first time that anti-GM-CSF attenuates esophageal epithelial eosinophilia, epithelial, and vascular remodeling and implicates GM-CSF signaling as a potential therapeutic target that warrants further investigation in EoE.
As with any mouse model, translation to clinical relevance is critical. However, this study suggests GM-CSF is a potential target that may offer new opportunities for the clinical management of patients with EoE.
One of the limitations of our study is the dosing regimen used. More frequent administrations may have been more completely effective. Equally, mice were treated by intraperitoneal administration of antibody. Current therapeutic approach in patients with EoE selectively targets the esophagus with orally administered steroids. Future studies should consider a mechanism to directly target the esophagus with antibody, or indeed with other molecular-inhibiting methodologies. The focus of the current study was the net effect on eosinophils, the effects on maturation and survival, specifically in the esophagus with or without anti-GM-CSF treatment. Other physiological effects may be altered via GM-CSF suppression. These include effects on antigenpresenting cell(s) as well as the effects of GM-CSF on the epithelium in EoE. What is known is that GM-CSF is overproduced by keratinocytes in atopic dermatitis, and this has implications for dendritic cell activation (20) . Our studies implicate anti-GM-CSF treatment in the reduction of angiogenic factors in the esophagus. In the human esophagus postirradiation and in a mouse model of esophageal overexpression of IKKbca, GM-CSF has been indicated in esophageal pro-angiogenic mechanisms (16, 37) . Thus, the pleiotropic factor GM-CSF may play multiple roles in EoE via direct effects on other cells. Future studies will aid in determining the potential impact of GM-CSF on the broad array of cells involved in EoE, such as esophageal epithelial cells, endothelial cells, resident and infiltrating esophageal antigen-presenting cells, and their indirect effects on eosinophils.
In summary, the present study highlights an important role for esophageal GM-CSF in regulating inflammatory patterns in a mouse model of EoE. Esophageal GM-CSF is increased in the context of eosinophilic inflammation, and these studies support its involvement in esophageal eosinophilia, basal cell hyperplasia, and vascular remodeling as potential therapeutic targets for the treatment of EoE.
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